Issue Cover

R & D

Pharmaceutical research and development updates

Articles

article-item
Strategic alliance announced between Recipharm and Exela for sterile manufacturing capabilities

Recipharm and Exela have announced that they have entered into an exclusive strategic alliance. The alliance between the two contract development and manufacturing organisations (CDMOs) aims to enhance sterile manufacturing capabilities in the US. As part of the alliance, Recipharm will be able to take advantage of Exela’s state-of-the-art manufacturing plant in Lenoir, NC, US.

10 October 2024R & D
article-item
Tiziana Life Sciences awarded $4m grant by NIH to study anti-CD3 in Alzheimer’s disease

Tiziana Life Sciences, a biotechnology company developing immunomodulation therapies, announced that the National Institutes of Health (NIH),'s National Institute on Aging has awarded a $4m grant to Dr Howard Weiner as principal investigator at Brigham and Women’s Hospital to be the key research site to study nasal anti-cd3 for the treatment of alzheimer’s disease (ad).

10 October 2024R & D
article-item
Next-generation sequencing partnership announced between ANGLE plc and NuProbe

Liquid biopsy company ANGLE plc has announced a partnership with NuProbe, a genomics and molecular diagnostics company, to utilise the latter’s pan-cancer next-generation sequencing (NGS) panel.

10 October 2024R & D
article-item
New collaboration agreement announced between EMIH association and the MTIG

The European Microbiome Innovation for Health (EMIH) association and the Microbiome Therapeutics Innovation Group (MTIG) have announced a new collaborative agreement. The agreement seeks to advance microbiome drug development by improving collaboration between the two microbiome focused coalitions.

10 October 2024Global
article-item
Santhera Pharmaceuticals announces LIONHEART study results for corticosteroid vamorolone

Santhera Pharma has announced the results of its LIONHEART study, which evaluated Vamorolone – a corticosteroid – and confirmed its action as a mineralcorticoid receptor antagonist (MRA).

9 October 2024Global
article-item
Cresset collaborates with Enamine to enable the design of new targeted protein degraders

Drug discovery company Cresset has announced the extension of its global collaboration with chemical and biological contract research organisation (cro) Enamine.

5 September 2024UK News
article-item
Johnson & Johnson’s MedTech announce orthopaedics receives 501K clearance from FDA

Orthopaedics branch of Johnson and Johnson Medtech, Depuy Synthes, has announced that their surgical robotics system velys active has received 501k clearance from the US Food and Drug Administration (FDA).

5 September 2024Europe
article-item
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development and co-commercialisation agreement – already investigating three dxd antibody drug conjugates (adcs) ‒ to include mk-6070.

5 September 2024Europe
article-item
AbbVie acquires Cerevel Therapeutics

AbbVie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline.

5 September 2024Europe
article-item
Merck to acquire Curon Biopharmaceutical’s B-cell depletion therapy

Merck (known as MSD outside the US and Canada) have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire cn201, a novel investigational clinical-stage bispecific antibody for the treatment of b-cell associated diseases.

5 September 2024UK News
article-item
Collaboration between global cancer center and Absci to use generative AI for therapeutics research

Memorial Sloan Kettering (MSK) have paired with Absci corporation to develop and discover new novel therapeutics through the use of generative artificial intelligence (genAI).

5 September 2024UK News
article-item
NeuroSense provides update for ALS treatment programme

NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study, which assessed Primec for the treatment of patients with amyotrophic lateral sclerosis (ALS).

24 July 2024R & D